Project Grant K23DK147870
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $2,076,999 to the University of Colorado-Denver on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a four-year project period extending through September 14, 2029. This Project Grant supports basic biomedical research investigating the role of mitochondrial dysfunction in Paneth cells as a mediator of inflammatory...
- Federal Project Grant Award Summary The University of Colorado-Denver received a $234,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, through September 14, 2027. The award funds research investigating the role of AIOLOS, a transcriptional repressor protein, in T cell-mediated pathogenesis of inflammatory bowel...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Colorado-Denver $756,480 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 5, 2025, for a project extending through June 30, 2030. This Project Grant supports research addressing critical evidence gaps in type 2 diabetes management by integrating real-world data from diverse patient populations with data from...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant of $949,759 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on May 15, 2026, with completion targeted for February 28, 2031. This award funds a real-world comparative effectiveness study of treatment options for membranous nephropathy (MN), an autoimmune kidney...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Colorado-Denver a $775,293 Project Grant on June 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of polyamines in cholestatic liver disease, specifically biliary atresia (BA). The research deliverables include fundamental scientific studies examining polyamine metabolism and...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Nemours Foundation a $114,000 Project Grant on May 12, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This 23-month research initiative, concluding April 30, 2028, develops and executes provider-focused dissemination strategies to advance the reach of evidence-based psychosocial care for youth with Type 1 Diabetes (T1D). The...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded University of Colorado-Denver $259,129 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a project examining the interactions between gut microbiome composition, intestinal development, and metabolic health following fetal growth restriction (FGR). The award, effective September 1, 2025, through May 31, 2030, supports research...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Regents of the University of Colorado-Denver a $797,416 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the period April 1, 2026 through March 31, 2029. The research project, titled "Immunogenetics in the Viral Etiology and Pathogenesis of Type 1 Diabetes," delivers targeted high-resolution genetic sequencing...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $824,078 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded April 1, 2026, with a completion date of January 31, 2030. The award funds a comprehensive research initiative titled "From Real-World Evidence to Systems Pharmacology: A Comprehensive Approach to...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $203,244 Project Grant to The Regents of the University of California, San Francisco (UCSF) effective July 1, 2026, through May 31, 2031, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports research to characterize real-world variation in pediatric intestinal failure treatment strategies and outcomes, leveraging the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Colorado-Denver a $192,826 Project Grant effective July 1, 2026, through March 31, 2031, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds comparative effectiveness research evaluating advanced therapies—including biologics and small molecule treatments—used to treat pediatric Crohn's disease. The research employs innovative pharmacoepidemiologic and causal inference methods to overcome treatment selection barriers and inform optimal medication matching for individual patients. The research project addresses a critical clinical gap in pediatric inflammatory bowel disease treatment. While over 10 advanced therapies are FDA-approved for adults with Crohn's disease, only two anti-tumor necrosis factor (anti-TNF) biologics are approved for children, constraining clinical decision-making. The funded research compares the clinical effectiveness of anti-TNF biologics with anti-interleukin biologics using a validated multicenter retrospective cohort in Aim 1, and validates findings through a prospective observational cohort study with patient-reported outcomes in Aim 2. This comparative effectiveness analysis is designed to account for demographic and disease-related confounders influencing treatment choice and ultimately improve treatment outcomes for the over 50,000 children in the United States affected by Crohn's disease.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 6/18/26 | ||
| Not listed | $192.8k | 6/15/26 |